Show simple item record

Structural Biology of Calcitonin: From Aqueous Therapeutic Properties to Amyloid Aggregation

dc.contributor.authorKAMGAR-PARSI, Kian
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorTOLCHARD, James
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorHABENSTEIN, Birgit
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorLOQUET, Antoine
dc.contributor.authorNAITO, Akira
dc.contributor.authorRAMAMOORTHY, Ayyalusamy
dc.date.accessioned2020-07-09T14:16:48Z
dc.date.available2020-07-09T14:16:48Z
dc.date.issued2017-07
dc.identifier.issn0021-2148
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10307
dc.description.abstractEnUnder appropriate conditions, peptides and proteins can assemble from their native state into prefibrillar oligomers and then mature into fibrillar aggregates. This transition forms the molecular basis of several pathologies, often related to the deposition of these amyloid fibrils. Several hormone peptides involved in fundamental biological processes have the tendency to self-assemble into amyloid fibrils, resulting in a loss of their native functions, and more importantly, entailing devastating consequences, such as the formation of amyloid depositions. Calcitonin is a 32 amino-acid hormone peptide that can be considered a molecular paradigm for the central events associated with hormone misfolding. Calcitonin in its native form is involved in various physiological functions, including mediating calcium homeostasis and maintaining bone structure. It is the latter function that has motivated the use of calcitonin as an aqueous therapeutic agent for the treatment of bone-related pathologies such as osteoporosis and Paget's disease. Despite some success as a therapeutic, calcitonin's ability to control these diseases is limited by its aggregation along the canonical amyloid aggregation pathway, compromising its long-term stability as a therapeutic agent. A better understanding of the misfolding process would not only provide the structural basis to improve calcitonin's long-term stability and activity as a therapeutic, but also provide valuable insights into pathological aggregation of other amyloids. In this work, we review the physiological roles of calcitonin, its structure, and aggregation process, and consider the effects of calcitonin's structure on its role as a therapeutic.
dc.title.enStructural Biology of Calcitonin: From Aqueous Therapeutic Properties to Amyloid Aggregation
dc.typeArticle de revue
dc.identifier.doi10.1002/ijch.201600096
dc.subject.halChimie/Matériaux
bordeaux.journalIsrael Journal of Chemistry
bordeaux.page634-650
bordeaux.volume57
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN) - UMR 5248*
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN, UMR 5248)
bordeaux.issue7-8
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Israel%20Journal%20of%20Chemistry&rft.date=2017-07&rft.volume=57&rft.issue=7-8&rft.spage=634-650&rft.epage=634-650&rft.eissn=0021-2148&rft.issn=0021-2148&rft.au=KAMGAR-PARSI,%20Kian&TOLCHARD,%20James&HABENSTEIN,%20Birgit&LOQUET,%20Antoine&NAITO,%20Akira&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record